Categories: All postsSpace

Maxar Technologies is not a stock to buy in 2019, this investor says

These are tough times for shareholders of Maxar Technologies (Maxar Technologies Stock Quote, Chart TSX:MAXR), which after a trying year in 2018 and a just as trying start to 2019 the company ended off February by taking an axe to its dividend, while announcing lower than expected quarterly revenues. All of which is to say that it could be time to cut your losses, says Don Lato of Padlock Investment Management, who says that the company’s debt ratio is just too unwieldy.

“They’re trying their best to make sure there’s some hope left. They’re trying to cut costs in a number of divisions but also to sell some of their holdings, to streamline the business to what they started out as and what they do best,” Lato, president of Padlock Investment, told BNN Bloomberg viewers Wednesday.

“If you hold it and you’re thinking about taking a loss, now is probably as good a time as any,” he says. “Certainly, if you do decide to hold it and it’s still trading at the same levels at the end of the year, I would definitely be looking at [selling] at that point. There’s just too much confusion, it’s too much of a disappointment and just too much debt.”

Maxar shares dropped 19 per cent at the end of February as the market responded to the company’s fourth quarter financials, which included an announcement of an organizational restructuring “to create a leaner and more agile business.” The company also cut its dividend from 37 cents per share in the previous quarter down to one penny. (All figures in US dollars.)

Maxar reported Q4 revenue of $496 million which was below the consensus expectation of $560.3 million and a net loss of $950 million or $16.10 per share, which compared to a profit of $55 million or 99 cents per share a year prior. The company’s long-term debt load grew to $3.03 billion for the period ended December 31, 2018, versus $3.94 billion a year earlier.

“The leverage ratio is about 4.2x and unless they can turn around some of those businesses they’re going to have further losses which is going to eat into that leverage ratio,” says Lato. “They’re okay on the covenants, they’re a little bit higher so there’s not immanent bankruptcy here, but it’s a long recovery road ahead.”

“I’d still be avoiding the stock. I came very close to buying it last summer and just didn’t pull the trigger, fortunately,” he says.

Tagged with: maxr
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Tilray: why this analyst just cut his price target

Haywood Securities analyst Neal Gilmer says lower Canadian cannabis market share is weighing on Tilray Brands (Tilray Brands Stock Quote,… [Read More]

19 hours ago

Why National Bank likes Anaergia right now

National Bank Financial analyst Baltej Sidhu says Anaergia’s (Anaergia Stock Quote, Chart, News, Analysts, Financials TSX:ANRG) divestiture of two legacy… [Read More]

19 hours ago

Canada’s provinces are leading investment boom, RBC says

RBC assistant chief economist Cynthia Leach says the public sector is playing a larger role in Canada’s investment boom than… [Read More]

20 hours ago

Can Eupraxia Pharmaceuticals stock go even higher?

Research Capital analyst Andre Uddin says Eupraxia Pharmaceuticals (Eupraxia Pharmaceuticals Stock Quote, Chart, News, Analysts, Financials TSX:EPRX) reported another strong… [Read More]

20 hours ago

Is it time to buy VersaBank stock?

Roth Capital Partners analyst Craig Irwin says VersaBank (VersaBank Stock Quote, Chart, News, Analysts, Financials NASDAQ:VBNK) is nearing a potential… [Read More]

20 hours ago

Rapid Micro Biosystems has a 240% upside, this analyst says

Roth Capital Partners analyst Max Masucci says Rapid Micro Biosystems (Rapid Micro Biosystems Stock Quote, Chart, News, Analysts, Financials NASDAQ:RPID)… [Read More]

20 hours ago